title: Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats.
abstract: BACKGROUND
  The central serotonergic systems are a major target for drugs used to treat neuropsychiatric disorders such as depression and schizophrenia in which disruption of frontal cortex function has been implicated. However, it is not known precisely how serotonin (5-HT) modulates the medial prefrontal cortex (mPFC) to affect cognitive function and behaviour.
  
  
  OBJECTIVE
  To investigate the roles of 5-HT(1A) and 5-HT(2A) receptors in mPFC on performance of the five-choice serial reaction time task (5CSRT), which assesses visuospatial attention, impulsivity and motivational processes.
  
  
  METHODS
  Following training on the 5CSRT, rats were implanted with bilateral guide cannulae aimed at the mPFC. Rats received intra-mPFC infusions of either 8-OH-DPAT (10, 30 and 100 ng) or M100907 (30, 100 and 300 ng) according to a Latin square design.
  
  
  RESULTS
  Both 8-OH-DPAT and M100907 selectively enhanced accuracy of target detection. When the stimulus duration was shortened, infusions of 8-OH-DPAT continued to improve accuracy, whereas M100907 decreased premature responding and omissions, thus partly dissociating the effects of these two compounds. Similar effects were obtained following systemic administration of M100907 and 8-OH-DPAT. The effects of 8-OH-DPAT were blocked by the 5-HT(1A) antagonist WAY 100635, at a dose that itself had no significant effects on behaviour.
  
  
  CONCLUSIONS
  These results indicate that modulation of 5-HT function within the mPFC via distinct receptors can enhance performance on the 5CSRT. These findings suggest a mechanism by which serotonergic agents improve cognitive function, which may be relevant to their therapeutic benefit in the treatment of neuropsychiatric disorders.
authors.affiliation: Department of Experimental Psychology, University of Cambridge, UK. caw42@cam.ac.uk
authors.forename: Catharine A
authors.initials: CA
authors.lastname: Winstanley
authors.forename: Yogita
authors.initials: Y
authors.lastname: Chudasama
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Dalley
authors.forename: David E H
authors.initials: DE
authors.lastname: Theobald
authors.forename: Jeffrey C
authors.initials: JC
authors.lastname: Glennon
authors.forename: Trevor W
authors.initials: TW
authors.lastname: Robbins
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000494:pharmacology*; D000818:Animals; D001288:Attention / Q000187:drug effects*; D001522:Behavior, Animal / Q000187:drug effects; D002755:Choice Behavior / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes / Q000662:veterinary; D005464:Fluorobenzenes / Q000494:pharmacology*; D007175:Impulsive Behavior; D008297:Male; D010880:Piperidines / Q000494:pharmacology*; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D011930:Reaction Time / Q000187:drug effects; D018490:Serotonin Agents / Q000494:pharmacology*; D012702:Serotonin Antagonists / Q000494:pharmacology*; D013037:Spatial Behavior / Q000187:drug effects
chemical_list: D005464:Fluorobenzenes; D010880:Piperidines; D018490:Serotonin Agents; D012702:Serotonin Antagonists; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; C079049:volinanserin